1. Home
  2. TRNO vs RYTM Comparison

TRNO vs RYTM Comparison

Compare TRNO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terreno Realty Corporation

TRNO

Terreno Realty Corporation

HOLD

Current Price

$66.06

Market Cap

7.0B

Sector

Finance

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$96.30

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNO
RYTM
Founded
2009
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
5.8B
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
TRNO
RYTM
Price
$66.06
$96.30
Analyst Decision
Buy
Strong Buy
Analyst Count
12
14
Target Price
$67.83
$131.14
AVG Volume (30 Days)
460.2K
597.1K
Earning Date
05-05-2026
05-05-2026
Dividend Yield
3.21%
N/A
EPS Growth
103.65
28.34
EPS
3.91
N/A
Revenue
$476,383,000.00
N/A
Revenue This Year
$8.42
$55.34
Revenue Next Year
$9.10
$86.06
P/E Ratio
$16.60
N/A
Revenue Growth
24.51
N/A
52 Week Low
$53.00
$55.31
52 Week High
$67.55
$122.20

Technical Indicators

Market Signals
Indicator
TRNO
RYTM
Relative Strength Index (RSI) 57.74 67.31
Support Level $59.39 $84.03
Resistance Level $66.97 $100.70
Average True Range (ATR) 1.67 4.05
MACD -0.15 1.14
Stochastic Oscillator 82.19 85.99

Price Performance

Historical Comparison
TRNO
RYTM

About TRNO Terreno Realty Corporation

Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: